Biosomic Technologies

BIOSOMICS™ is the biotechnology unit of Linkcare Health Services dedicated to design Point-of-Care in-vitro-diagnostic devices for screening of diseases where early detection provides a breakthrough improvement in the prognosis. Since 2020 Linkcare ‘s LINKCARE BIOSCREENING™unit is a registered European in-vitro diagnostics manufacturer (EUDAMED registration number: ES-MF-000033782). Current research areas are in the field of early detection of cancer, under the brand ONCOSOMIX™, and neurodegenerative diseases, under the brand NEUROSOMIX™. TECHNOLOGY BIOSOMICS has developed a proprietary technology able to analyse the breakdown of up to 4 selected biomarkers in the desired extracellular vesicles targets. This allows to detect in a single blood drop the presence of cancer-derived and neuron-derived extracellular vesicles (oncosomes and neurosomes, respectively) providing a "liquid-biopsy" approach to disease screening. RESEARCH PIPELINES ONCOSOMIX focuses on the early detection of cancer by detecting the presence of circulating oncosomes in blood or plasma samples. ONCOSOMIX’s research focuses on those cancers where detection is available only in late disease stages. Current targets include lung, colon and pancreatic cancer. NEUROSOMIX focuses on the early detection neurodegenerative diseases by detecting the presence of circulating neurosomes in blood or plasma samples. NEUROSOMIX’s research focuses on detecting abnormal protein-aggregates in neuron derived extracellular vesicles such as alpha-synclein isoforms and phosphorylated-tau found in neurodegenerative diseases such as Parkinson's and Alzheimer's disease, respectively.